Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Kintor Approved to Start Phase I Trial of Dual-Targeting Antibody

publication date: Oct 22, 2021

Suzhou Kintor Pharma was approved to start a Phase I China trial of its dual-targeting PD-L1/TGF-β antibody in advanced solid tumors. According to the company, GT90008 has high inhibiting activity of both PD-L1 and TGF-βR2 with potential to be a best-in-class drug globally. In August 2020, Kintor acquired Greater China rights for GT90008 from Gensun, a US company. Kintor is a clinical-stage biotech that develops innovative small molecule and biological therapeutics for androgen-receptor-related diseases. More details....

Stock Symbol: (HK: 9939)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.